Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS), 'we think the entire package presents a relatively convincing picture'
August 9, 2022 4:02 AM EDTStifel analyst Annabel Samimy reiterated a Buy rating and $60.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "While we await a seminal decision on pegcetacoplan in GA (11/26/22), APLS continues to execute on the Empaveli/PNH commercial launch, with sales reaching $16.3mn/Cons.... More
Cowen Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS), 'We Remain Optimistic For Pegcetacoplan Approval'
August 9, 2022 4:01 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and $70.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "We continue to view the acceptance, granting of Priority Review for the sNDA for pegcetacoplan in GA and the fact that the... More
Roth Capital Reiterates Sell Rating on Apellis Pharmaceuticals (APLS), Street Low $40 PT
August 9, 2022 3:58 AM EDTRoth Capital analyst Elemer Piros reiterated a Sell rating and $40.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "We arrive at our 12-month price target of $40/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from pegcetacoplan for treatment PNH... More
Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5c
August 8, 2022 4:18 PM EDTApellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.46), $0.05 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $16.95 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
... More